Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arch Biopartners Inc (ARCH.VN)

Arch Biopartners Inc (ARCH.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
U.S. Eases into Memorial Day Weekend

Monday U.S. Markets are Closed for Memorial Day Tuesday U.S. Economic Lookahead S&P ...

ARCH.VN : 1.600 (-1.23%)
DAC.VN : 0.035 (-30.00%)
EGT.VN : 0.010 (unch)
HEI.A : 178.98 (-0.19%)
DAC : 88.33 (+1.24%)
MOMO : 6.64 (-3.07%)
CRM : 255.15 (+0.46%)
A : 131.96 (-0.20%)
HPQ : 37.00 (+0.74%)
COST : 855.85 (+1.54%)
DELL : 139.09 (-0.34%)
MRVL : 73.97 (+0.52%)
Stocks in play: Arch Biopartners Inc.

Announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee ...

ARCH.VN : 1.600 (-1.23%)
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage...

ARCH.VN : 1.600 (-1.23%)
ACHFF : 1.1900 (-0.42%)
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

ARCH.VN : 1.600 (-1.23%)
ACHFF : 1.1900 (-0.42%)
Shares for Interest Debt Settlement

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the...

ARCH.VN : 1.600 (-1.23%)
ACHFF : 1.1900 (-0.42%)
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

ARCH.VN : 1.600 (-1.23%)
ACHFF : 1.1900 (-0.42%)
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe...

ARCH.VN : 1.600 (-1.23%)
ACHFF : 1.1900 (-0.42%)
Unaware of Any Undisclosed Material Change

TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc....

ARCH.VN : 1.600 (-1.23%)
ACHFF : 1.1900 (-0.42%)
Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

ARCH.VN : 1.600 (-1.23%)
ACHFF : 1.1900 (-0.42%)
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

ARCH.VN : 1.600 (-1.23%)
ACHFF : 1.1900 (-0.42%)

Barchart Exclusives

1 'Strong Buy' Small-Cap With 276% Upside Potential
As Jasper embarks on promising clinical trials and reports narrower losses, analysts remain bullish, setting ambitious price targets that could indicate substantial returns for investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar